Kin MBA - HUTCHMED (China) Sr Devel
| HMDCF Stock | USD 3.66 0.00 0.00% |
Insider
Kin MBA is Sr Devel of HUTCHMED Limited
| Age | 46 |
| Phone | 852 2128 1188 |
| Web | https://www.hutch-med.com |
HUTCHMED (China) Management Efficiency
The company has return on total asset (ROA) of (0.1932) % which means that it has lost $0.1932 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2472) %, meaning that it generated substantial loss on money invested by shareholders. HUTCHMED (China)'s management efficiency ratios could be used to measure how well HUTCHMED (China) manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kin Li | Sihuan Pharmaceutical Holdings | 35 | |
| Mauricio Christovam | Hypera SA | N/A | |
| Sean Capazorio | Aspen Pharmacare Holdings | 56 | |
| Juliana Salem | Hypera SA | N/A | |
| James Shorris | Curaleaf Holdings | 61 | |
| Dip MBA | Aspen Pharmacare Holdings | 47 | |
| Stavros Nicolaou | Aspen Pharmacare Holdings | 58 | |
| HansGeorge Feldmeier | Dermapharm Holding SE | N/A | |
| Joseph Bayern | Curaleaf Holdings | 60 | |
| Tang Lee | Haw Par | N/A | |
| Jakob Feinstein | Curaleaf Holdings | N/A | |
| Kun Chiew | Haw Par | N/A | |
| BCom BCom | Aspen Pharmacare Holdings | 61 | |
| Peter JD | Curaleaf Holdings | 55 | |
| Zizipho Mmango | Aspen Pharmacare Holdings | 38 | |
| Brian Loo | Haw Par | N/A | |
| Edward Kremer | Curaleaf Holdings | 51 | |
| Andreas Eberhorn | Dermapharm Holding SE | 48 | |
| Yanling Chen | Sihuan Pharmaceutical Holdings | 45 | |
| Guili Miao | Sihuan Pharmaceutical Holdings | 50 | |
| Joe Holland | Curaleaf Holdings | N/A | |
Management Performance
| Return On Equity | -0.25 | |||
| Return On Asset | -0.19 |
HUTCHMED Limited Leadership Team
Elected by the shareholders, the HUTCHMED (China)'s board of directors comprises two types of representatives: HUTCHMED (China) inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HUTCHMED. The board's role is to monitor HUTCHMED (China)'s management team and ensure that shareholders' interests are well served. HUTCHMED (China)'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HUTCHMED (China)'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Selina Zhang, VP HR | ||
| Kin MBA, Sr Devel | ||
| Karen Atkin, Ex COO | ||
| CA BEc, CFO Director | ||
| CS CGP, Company Director | ||
| Charles Nixon, Group Counsel | ||
| Qingmei Wang, Sr Alliances | ||
| Hong Chen, VP China | ||
| ACGI BSc, Ex Chairman | ||
| Weiguo BSc, Chief CEO |
HUTCHMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is HUTCHMED (China) a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.64) % | |||
| Operating Margin | (0.95) % | |||
| Current Valuation | 1.66 B | |||
| Shares Outstanding | 864.77 M | |||
| Shares Owned By Insiders | 44.52 % | |||
| Shares Owned By Institutions | 54.00 % | |||
| Price To Book | 3.03 X | |||
| Price To Sales | 6.53 X |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in HUTCHMED Pink Sheet
HUTCHMED (China) financial ratios help investors to determine whether HUTCHMED Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HUTCHMED with respect to the benefits of owning HUTCHMED (China) security.